Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Clinical trial NCT07250269 · RECRUITING
Trial details
- NCT number
- NCT07250269
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-29
- Primary completion
- 2028-11-24
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.